BECTON DICKINSON & CO — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Becton Dickinson reported Q3 FY2026 continuing operations revenue of $4.983B (+5.4% reported, +4.4% FXN) and adjusted diluted EPS of $3.23 (+4.9% reported, +3.9% FXN). The company completed spinoff of Biosciences/Diagnostic Solutions to Waters on February 9, 2026. BD raised full-year adjusted EPS guidance midpoint from $12.62 to $12.72, now targeting $12.62–$12.72 (prior: $12.52–$12.72), and expects revenue growth toward high end of low single-digit-plus range. Year-to-date operating cash flow increased 33.3% to $2.1B; free cash flow rose 44.6% to $1.7B.
Why this rating
Modest guidance raise and solid post-spinoff execution; modest relative to $65.5B market cap; no transformational event but steady operational momentum in 'New BD' structure.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.